Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khandan Keyomarsi

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2018
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase InhibitionXian Chen, Kwang-Huei Low, Angela Alexander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, et al.
NPJ Breast Cancer|December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screenNealia C House, Maxine M Chen, Sima Khazaei, et al.
Nature Communications|January 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 inductionLinjie Luo, Yan Wang, Tuyen Bui, et al.
Pharmacological Reviews|March 27, 2025
Cell cycle dysregulation in cancerAntonino Glaviano, Samarendra K Singh, E Hui Clarissa Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 24, 2005
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancerAstrid M Eder, Xiaomei Sui, Daniel G Rosen, et al.
BMC Genomics|February 21, 2018
Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypesYuanxin Xi, Jiejun Shi, Wenqian Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> AmplificationSiqing Fu, Shuyang Yao, Yuan Yuan, et al.
Leukemia|March 12, 2024
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon responseBhakti Patel, Yifan Zhou, Rachel L Babcock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2019
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast CancerNicole M Kettner, Smruthi Vijayaraghavan, Merih Guray Durak, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2018
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase InhibitionXian Chen, Kwang-Huei Low, Angela Alexander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, et al.
NPJ Breast Cancer|December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screenNealia C House, Maxine M Chen, Sima Khazaei, et al.
Nature Communications|January 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 inductionLinjie Luo, Yan Wang, Tuyen Bui, et al.
Pharmacological Reviews|March 27, 2025
Cell cycle dysregulation in cancerAntonino Glaviano, Samarendra K Singh, E Hui Clarissa Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 24, 2005
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancerAstrid M Eder, Xiaomei Sui, Daniel G Rosen, et al.
BMC Genomics|February 21, 2018
Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypesYuanxin Xi, Jiejun Shi, Wenqian Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> AmplificationSiqing Fu, Shuyang Yao, Yuan Yuan, et al.
Leukemia|March 12, 2024
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon responseBhakti Patel, Yifan Zhou, Rachel L Babcock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2019
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast CancerNicole M Kettner, Smruthi Vijayaraghavan, Merih Guray Durak, et al.
Pageof 11